Acquisitions · Biotechnology
Otsuka buys antibody drug developer Visterra for about $430 million
- Buyer
- Otsuka Pharmaceutical (via Otsuka America) (Tokyo)
- Target
- Visterra, Waltham, Massachusetts
- Value
- About $430M cash
- Status
- Completed on August 31, 2018.
- Date
- 2018-07-11
Otsuka Pharmaceutical, through Otsuka America, bought Visterra, a Waltham, Massachusetts biotech company developing antibody therapies, for about $430 million in cash.
Why it matters
The deal added an antibody research platform in the Boston area biotech cluster to Otsuka's drug pipeline.
Sources
Kakehashi M&A News home
